Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Johnson & Johnson (JNJ) is working to take up the production of cancer medicine, Doxil, by September 2012 to increase the supply.
Subscribe to our email newsletter
Production at Boehringer Ingelheim’s Ben Venue Laboratories factory in Ohio, US, was stopped in November 2011 due to product quality issues.
Ben Venue said it may resume operations by the end of 2012, the Bloomberg reported.
The New Brunswick spokeswoman Lisa Vaga was quoted by Bloomberg as saying that J&J plans to transfer the manufacturing to another supplier.
J&J plans to allow Ben Venue formulate the medication and then transfer it to another company for the filling and packaging of the product.